Rystiggo (rozanolixizumab-noli) / UCB 
Welcome,         Profile    Billing    Logout  
 0 Diseases   10 Trials   10 Trials   90 News 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rystiggo (rozanolixizumab-noli) / UCB
NCT04650854 / 2020-003230-20: A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis

Completed
3
165
Europe, Canada, Japan, US, RoW
Rozanolixizumab, UCB7665
UCB Biopharma SRL
Generalized Myasthenia Gravis
01/24
01/24
NCT05681715 / 2022-003870-21: A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

Completed
3
62
Europe, Canada, Japan, US, RoW
Rozanolixizumab
UCB Biopharma SRL, UCB Biopharma SRL
Generalized Myasthenia Gravis
04/24
04/24
NCT06540144: An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

Enrolling by invitation
3
12
Europe, RoW
rozanolixizumab, UCB7665
UCB Biopharma SRL
Generalized Myasthenia Gravis
08/27
08/27
cosMOG, NCT05063162 / 2021-000352-19: A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)

Recruiting
3
104
Europe, Japan, US, RoW
Rozanolixizumab, UCB7665, Placebo, PBO
UCB Biopharma SRL
Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)
05/27
07/27
roMyG, NCT06149559: A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis

Recruiting
2/3
12
Europe, US, RoW
rozanolixizumab, UCB7665
UCB Biopharma SRL
Generalized Myasthenia Gravis
06/26
08/26
NCT05643794: A Proof-of-concept Study to Evaluate the Efficacy and Safety of Rozanolixizumab to Treat Adult Study Participants With Severe Fibromyalgia Syndrome

Completed
2
63
Europe
rozanolixizumab, UCB7665, Placebo, PBO
UCB Biopharma SRL
Fibromyalgia
05/24
07/24
AIE001, NCT04875975 / 2019-004778-25: A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

Terminated
2
12
Europe, US, RoW
Rozanolixizumab, Placebo
UCB Biopharma SRL
Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
03/24
04/24
NCT06720714: A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women

Recruiting
1
20
US
Rozanolixizumab, UCB7665
UCB Biopharma SRL
Healthy Participants
06/25
06/25
NCT05014724: CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)

No Longer Available
N/A
NA
Rozanolixizumab
UCB Biopharma SRL
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
 
 

Download Options